What does it take to go from performing reconstructive plastic surgeries at Harvard to becoming a managing partner at one of biotech's most focused venture firms? Rich Gaster, Managing Partner at venBio Partners, joins Mike and Jen to trace a career path that runs through Stanford MD-PhD training, two grad school startups, the company-building engine at Third Rock Ventures, and the founding team of Pliant Therapeutics — before landing at venBio, where he helped engineer three back-to-back acquisitions in a single quarter.

Rich breaks down what makes venBio's small-team, high-conviction model so effective, how asset-focused investing differs from platform company builds, and what he looks for when deciding to pull the trigger on a deal. He also shares hard-won advice for the next generation of biotech investors — including why thinking like an investor during your training matters more than your degree.

The conversation closes with Rich sharing the deeply personal story of his daughter Claire's diagnosis with ATRT, an ultra-rare pediatric brain cancer with a 30% two-year survival rate — and how his medical training, network, and willingness to fight the system helped save her life. He also discusses his work with the Pediatric Brain Tumor Foundation and how others in the VC and biotech community can get involved.

Join Team Claire by donating here: https://curethekids.org/teamclaire_wsgr

Dr. Anna French, Managing Partner at Qiming Venture Partners USA, joins the NextGen VC Podcast to trace her nonlinear path from an Oxford DPhil and BCG boardrooms to becoming employee #1 at one of biotech's most globally connected venture firms. 
Anna shares what it's really like to build a fund from the ground up, why she championed Umoja Biopharma's bold bet on in vivo CAR-T and in-house manufacturing, and how a global perspective — forged in UK labs, Korean hospitals, and Parisian roundtables — shapes the way she looks for innovation. She shares candidly about LP fundraising, the US-China biotech opportunity, and what work-life balance actually looks like when both you and your spouse are running full speed. 

Suan Tuang didn’t take a traditional path into biotech investing, and this journey shapes how he evaluates risk today. Now at TCG Crossover, and with prior experience at Foresite and Eventide, Suan brings a clinician-scientist lens to investing across private and public markets. In this episode, Suan shares how his immigrant journey and academic challenges at MIT and Harvard have shaped his unique approach to risk and resilience. Learn how he leverages clinical data over hype, balances scientific rigor with market realities, and more. Suan also offers practical advice for aspiring investors and entrepreneurs. Tune in for actionable insights and inspiration. 

This episode may feature current or former clients of Wilson Sonsini. This podcast is for general informational purposes and is not intended to provide and should not be relied on as legal advice. The information in this podcast is not tailored to a particularized situation or jurisdiction, may not reflect the current state of the law, and should not be considered a substitute for the advice of your own legal counsel. You should not consider this podcast an invitation to form an attorney-client relationship, and no attorney-client relationship is created by your use of this podcast. Wilson Sonsini disclaims all liability in respect to any actions taken or not taken based on the content of this podcast and notes that prior results do not guarantee a similar outcome. This podcast may be considered attorney advertising in certain jurisdictions.

What does it take to turn breakthrough science into a breakthrough company? In this episode of the NextGen VC Podcast, we sit down with Noreen Rizvi, Principal at Third Rock Ventures, whose journey from chemical engineering to venture creation offers a rare look inside the art and science of biotech investing. Noreen discusses how she bridges science and strategy, what she’s learned from building companies like Trace Neuro and Faze Medicine, and why Third Rock spends years incubating ideas before launch. She also shares how mentorship, collaboration, and a “take the call” mindset have shaped her path. Tune in for a grounded, inside look at company creation, risk-taking, and the evolving biotech landscape from RNA therapeutics to the next generation of life science innovation.

This episode may feature current or former clients of Wilson Sonsini. This podcast is for general informational purposes and is not intended to provide and should not be relied on as legal advice. The information in this podcast is not tailored to a particularized situation or jurisdiction, may not reflect the current state of the law, and should not be considered a substitute for the advice of your own legal counsel. You should not consider this podcast an invitation to form an attorney-client relationship, and no attorney-client relationship is created by your use of this podcast. Wilson Sonsini disclaims all liability in respect to any actions taken or not taken based on the content of this podcast and notes that prior results do not guarantee a similar outcome. This podcast may be considered attorney advertising in certain jurisdictions.

Join us on the NextGenVC Podcast as we dive into the inspiring journey of Dr. Tia Lyles-Williams, a trailblazer in the biotech industry. Discover how mentorship shaped her path, the challenges she overcame, and her vision for inclusive biotech innovation through her accelerator, HiveBio. Dr. Tia shares insights on building a community-driven biotech ecosystem and the importance of perseverance in the face of obstacles. Tune in for an engaging conversation that highlights the dynamic world of venture capital and biotech in Philadelphia.

Hosts Mike Hostetler and Jen Fang are joined by Jon Chee, CEO of Excedr and host of The Biotech Startups Podcast. Jon shares insights from his work with early-stage life science companies, trends he's observing in biotech, and what he’s learned from interviewing founders and industry leaders on his own podcast. He also reflects on the importance of company culture, capital structure, and resilience in building successful biotech ventures. Tune in to hear how Jon is helping founders navigate startup challenges, scale smarter, and stay focused on science.

In this episode, hosts Jen Fang and Mike Hostetler welcome guest Ran Geng, a Principal on the Private Equity Team at OrbiMed. The discussion covers the unique opportunities and challenges in the Chinese market, including government policies, the rise of tech startups, and more. They also explore the influence of China's rapid technological advancements, current investment trends, and strategies investors can adopt to succeed in this quickly evolving landscape. 

In this episode of the NextGenVC podcast, hosts Jen Fang and Mike Hostetler are joined by Chris Garabedian, founder of Xontogeny and biopharma veteran, to discuss the transformative impact of early-stage biotech investment. Chris shares his journey from biotech corporate leadership to venture capital, emphasizing the importance of thoughtful drug development and the value of nurturing early-stage companies. He explains the inception of Xontogeny, its collaboration with Perceptive Advisors, and the unique venture incubation model they follow. Chris also highlights the essential qualities for success in biotech investing and offers insights for budding entrepreneurs and potential VCs alike.

On this episode of the NextGen VC Podcast, we’re joined by Dr. Josep Bassaganya-Riera, the president and CEO of NImmune Biopharma and founder of The NIMML Institute, a nonprofit research organization. A scientist turned entrepreneur, Josep shares his journey from academia to launching multiple biotech ventures, including Lando Biopharma (acquired by AbbVie). He reflects on the pivotal moments that led him to leave the university world and build companies at the intersection of science and innovation. We dive into the early stages of company formation, his experiences working with investors like Chris Garabedian and Perceptive Advisors, and why maintaining control over company direction and governance is critical—especially for repeat founders. Josep also shares insights on the future of immunotherapy and the promise of precision medicine in treating autoimmune and inflammatory diseases. Don’t miss this fascinating conversation!

In this episode of the Next Gen VC podcast, hosts Mike Hostetler and Jen Fang sit down with Felix Breyer from J.P. Morgan Life Sciences Private Capital. Felix, with a background as a molecular and cellular biologist, dives deep into the critical role of private capital in life sciences and biotech. He shares his journey from academia to venture capital, emphasizes the importance of mentorship, and provides an insider's perspective on the evolving landscape of biotech investing. Tune in to explore key trends, challenges, and opportunities in the biotech sector, and gain valuable insights for aspiring venture capitalists. Sponsored by Wilson Sonsini and Launch Bio.